Trastuzumab as Single Agent Therapy for HER2-Positive Metastatic Breast Cancer

Publisher： Karger

E-ISSN： 2296-5262|33|8-9|420-421

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.33, Iss.8-9, 2010-07, pp. : 420-421

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Docetaxel plus trastuzumab as treatment for HER-2 positive metastatic breast cancer: review of the existing evidence

By Demonty Gaston  

Women's Health, Vol. 3, Iss. 5, 2007-09 ,pp. : 523-528

Future Medicine

Access to resources Recommend Favorite

Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2‐positive metastatic breast cancer

By  

CANCER, Vol. 120, Iss. 13, 2014-07 ,pp. : 1932-1938

John Wiley & Sons Inc

Access to resources Recommend Favorite

Re-Evaluation of HER2 Status in Metastatic Breast Cancer and Tumor-Marker Guided Therapy with Vinorelbine and Trastuzumab

By  

Oncology Research and Treatment, Vol. 28, Iss. 2, 2005-02 ,pp. : 95-97

Karger

Access to resources Recommend Favorite

Will trastuzumab change the optimal adjuvant systemic therapy of patients with HER2-positive breast cancer?

By Santini Daniele   Vincenzi Bruno   Tonini Giuseppe  

Women's Health, Vol. 2, Iss. 1, 2006-01 ,pp. : 1-3

Future Medicine

Access to resources Recommend Favorite

Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer

By Boyraz Baris   Sendur Mehmet A.N.   Aksoy Sercan   Babacan Taner   Roach Emir C.   Kizilarslanoglu Muhammet C.   Petekkaya Ibrahim   Altundag Kadri  

Current Medical Research and Opinion, Vol. 29, Iss. 4, 2013-04 ,pp. : 405-414

Informa Healthcare

Access to resources Recommend Favorite